Remote Oncology Consultation Questions: What Should You Ask?
- MedBridgeNZ
- Aug 4
- 15 min read
A remote oncology consultation can provide another specialist’s perspective without requiring the patient to travel immediately. Its usefulness, however, depends partly on whether the specialist receives relevant medical records and clearly prioritised questions.
The most useful remote oncology consultation questions go beyond asking, “What treatment do you recommend?” They should clarify what the submitted records show, what remains uncertain, why an option is being discussed, how safety and treatment response would be monitored, and whether the next step could take place locally.
In this article, “remote oncology consultation” may refer to a record-based specialist second opinion or a scheduled remote discussion, depending on the physician and institution.
Key Takeaways
Begin with the decision the patient and family need help making.
Ask which conclusions can be reached from the submitted records and which require updated tests or an in-person examination.
Treatment questions should cover the purpose, limitations, safety requirements, monitoring plan, and alternatives.
For an international consultation, ask separately what can be managed locally and what may genuinely require travel.
Quick Answer
Before a remote cancer consultation, prepare a focused list of questions that can help the specialist address the patient’s next decision. Ask about:
whether the diagnosis and current disease status are sufficiently documented;
which important records or tests are missing;
the purpose and limitations of each treatment option;
patient-specific factors that may affect safety or suitability;
how treatment response and adverse effects would be monitored;
whether the suggestions could be discussed or implemented locally;
which parts of the assessment require an in-person consultation;
what remains uncertain after the records have been reviewed.
Patients do not need to ask every possible question. The priority should be the questions that affect the next treatment, testing, or travel decision.
Important Safety Note:
A remote second opinion should not delay emergency assessment, urgent symptom management, or local care for severe or rapidly worsening symptoms.
15 Remote Oncology Consultation Questions to Ask
The following checklist can be adapted to the patient’s diagnosis, previous treatment, and current concerns.
Do the submitted pathology and imaging records clearly support the diagnosis?
Is any important medical information missing, unclear, or outdated?
What is your interpretation of the patient’s current disease status?
What is the main purpose of the proposed treatment option?
Which options warrant discussion with the patient’s current oncologist?
What patient-specific factors may limit or exclude those options?
Are further pathology, imaging, or laboratory tests required?
How would the treating team determine whether treatment is helping?
What common and serious side effects should the patient understand?
Which symptoms would require urgent local medical attention?
How do previous treatments affect the remaining options?
Do any genomic or biomarker findings have an established treatment implication?
Could the suggested tests or treatment be considered locally?
Which parts of the assessment require an in-person examination?
What remains uncertain after reviewing the available records?
This checklist is a starting point rather than a script. A shorter set of prioritised questions may produce a more focused response than a long list covering unrelated concerns.
Why Can Broad Questions Produce an Unclear Second Opinion?
A question such as “What is the best treatment?” may sound reasonable, but it is often too broad to answer from overseas medical records alone. The specialist may not know:
whether the original pathology has been independently confirmed;
whether the latest scan reflects the patient’s current condition;
why a previous treatment was stopped;
which adverse effects occurred during earlier treatment;
whether current organ function limits certain options;
what treatments are available in the patient’s home country;
whether the patient is seeking local treatment guidance or considering travel.
A more focused question identifies the decision being considered.
Instead of asking:
What is the best treatment?
Consider asking:
Based on the submitted pathology, imaging, and previous treatment history, which options warrant discussion with the patient’s current oncologist, and what limits your opinion?
This gives the specialist a defined question while recognising the limitations of a record-based review.
What Is a Remote Oncology Consultation?
Definition:A remote oncology consultation is a cancer specialist review conducted without the patient initially attending the overseas hospital in person.
Function:The specialist examines the available records and comments on a defined diagnosis, treatment plan, or unresolved clinical question.
Typical Use Case:It may be considered when a diagnosis is complex, the cancer has progressed after previous treatment, the family wants another specialist perspective, or international travel would require substantial preparation.
Why This Matters:A remote consultation may help distinguish between options that can be discussed with the current treating team and those that require further testing or an in-person institutional assessment. It does not automatically confirm treatment eligibility, hospital admission, or fitness to travel.
Start With the Decision the Family Needs to Make
Before preparing individual questions, complete this sentence: After receiving this consultation, we need to decide whether…
Possible endings include:
to continue the current treatment;
to discuss another option with the local oncologist;
to request further pathology or molecular testing;
to obtain updated imaging;
to seek an in-person consultation in China;
to postpone travel until the patient’s condition is more stable;
to prioritise symptom management;
to gather further information before making a decision.
This statement helps the specialist understand the purpose of the consultation.
It also separates three types of information:
What the submitted records support
What remains uncertain
What requires further testing or examination
What Should You Ask About the Diagnosis and Missing Information?
Ask whether the submitted pathology, imaging, and clinical history are sufficient to address the main consultation question.
Useful questions include:
Do the pathology and imaging records support the diagnosis provided?
Is a pathology re-review advisable?
Are the submitted scans recent enough for the question being asked?
Is there any inconsistency between the pathology, imaging, and clinical summary?
Which sites of disease are most relevant to the current decision?
Are further laboratory tests or imaging studies required?
Does another specialty need to examine part of the case?
Which conclusions cannot be reached from the submitted materials?
For recurrent or metastatic cancer, the family may also ask:
Is the available information sufficient to confirm progression?
Could the apparent progression require comparison with earlier imaging?
Do current symptoms change the urgency or purpose of treatment?
Would updated organ-function tests materially change the opinion?
The purpose is not to ask the specialist to repeat the entire medical history. It is to identify which facts affect the next decision.
What Should You Ask About Treatment Goals and Patient Suitability?
Ask what the proposed option is intended to achieve and which patient-specific factors may affect whether it can reasonably be considered. A treatment may be discussed to:
slow or control disease progression;
reduce symptoms;
address a particular lesion;
stabilise a complication before another treatment;
provide an alternative after previous therapy;
preserve function or quality of life;
obtain more information before selecting a longer-term plan.
Questions may include:
What is the intended goal of this option?
Is the aim disease control, symptom relief, or both?
Which findings in the records support discussing it?
Which findings make you cautious about it?
How do previous treatments affect its potential relevance?
Are there organ-function or performance-status requirements?
Could current medicines interact with the proposed treatment?
Would another specialist need to provide clearance?
Is the option standard, investigational, or used outside its usual approved indication?
What circumstances would make it inappropriate?
The existence of a treatment does not establish that it is appropriate for every patient with the same diagnosis. A remote report should distinguish between an option that warrants discussion and a treatment formally accepted by a hospital after current examination and testing.
What Should You Ask About Side Effects and Safety Monitoring?
Ask which risks apply to the exact treatment being discussed and how the patient would be monitored. Useful questions include:
What are the more common side effects of this treatment?
Which serious adverse effects require urgent attention?
Which risks are particularly relevant to the patient’s age or medical history?
What baseline tests are required?
Which blood tests or vital signs would need monitoring?
Could adverse effects occur after the patient returns home?
Which symptoms require contacting the oncology team?
Which symptoms require emergency local care?
Who would manage complications during treatment?
Could the local medical team provide part of the monitoring?
Side effects vary substantially according to the medicine, combination, dose, treatment schedule, previous therapy, and baseline health. The consulting specialist and prescribing physician should identify the risks relevant to the specific treatment. MedBridgeNZ does not determine whether a treatment is medically safe or appropriate.
What Should You Ask About Treatment Response and Imaging?
Ask how the treating team would define benefit, which tests would be used, and what findings might lead to continuing, adjusting, or stopping treatment. Questions may include:
What clinical findings would indicate that treatment is helping?
Which imaging method would normally be used for monitoring?
Is CT, MRI, PET-CT, or another test relevant to this cancer?
What baseline imaging is required?
When would an initial response assessment normally be considered?
Could symptoms or laboratory results require an earlier review?
What would count as response, stable disease, or progression?
What would happen if the initial assessment showed no benefit?
Could monitoring be completed by the patient’s local oncology team?
“Will this treatment work?” generally cannot be answered with certainty before treatment begins. Treatment and imaging timelines also vary according to the disease, protocol, and patient’s condition. A timetable used for one patient should not be treated as a standard schedule for another.
What Should You Ask About Genomic or Biomarker Results?
A genomic finding does not automatically identify an effective treatment. Its relevance depends on the type of alteration, the cancer involved, the quality of the test, and the available clinical evidence. Ask:
Is the alteration pathogenic or a variant of uncertain significance?
Is it clinically relevant to this cancer type?
Does it have an established treatment implication?
Is the proposed medicine approved, investigational, or used outside its usual indication?
Should the result be confirmed or supplemented with further testing?
Terminology should also be checked carefully. For example, PD-1 and PD-L1 are related but different treatment targets. Any inconsistency between the original records, translation, and specialist report should be clarified.
Can the Specialist’s Suggestions Be Discussed With the Local Oncologist?
Ask which parts of the overseas opinion can be discussed, investigated, or carried out locally. A specialist may discuss an approach that:
is already available in the patient’s home country;
is available under another medicine name or brand;
requires local regulatory approval;
requires monitoring by a physician who can examine the patient;
depends on resources available only at certain institutions;
cannot be prescribed across jurisdictions.
Questions may include:
Which parts of the opinion can be discussed with the current oncologist?
Could the suggested tests be completed locally?
Could the proposed treatment be administered locally?
What information should the local oncologist review?
Who would be responsible for prescribing and monitoring treatment?
Does the report contain enough detail for another oncologist to understand the rationale?
What should happen if the local and overseas physicians interpret the case differently?
A second opinion is additional clinical input. It is not a direct prescription that the patient must follow.
What Can Be Managed Locally—and What May Require Travel?
Ask whether the proposed pathway genuinely requires treatment in China or whether the consultation can first support a local-care discussion. Important questions include:
Does this pathway require treatment in China?
Which part of the assessment must take place in person?
Is hospital acceptance confirmed or still conditional?
Would tests need to be repeated after arrival?
Could the in-person examination lead to a different plan?
Could part of the treatment or monitoring take place locally?
Should the current physician comment on fitness for long-haul travel?
What clinical or administrative conditions remain unresolved?
Patients who have not yet identified an institution can review MedBridgeNZ’s featured hospital profiles for general information about hospital type, location, international-patient departments, and listed specialty areas.
A remote review may result in:
continued local care;
further testing;
discussion of another option with the current team;
an in-person consultation;
postponement of travel;
a decision that overseas travel is not currently appropriate.
Treatment suitability and travel suitability are separate questions. Hospital availability, admission requirements, travel documentation, and institutional policies should be confirmed for the specific patient and institution. If an in-person visit is later confirmed, patients can review the China medical travel visa guide for an overview of possible entry pathways and the administrative questions that should be verified before travel.
From Broad Questions to Decision-Ready Questions
Broad Question | More Decision-Ready Question | Why It Is More Useful |
What is the best treatment? | Based on the submitted pathology, imaging, and previous treatment, which options warrant discussion with the current oncologist, and what limits your opinion? | Defines the evidence and acknowledges uncertainty |
Will it work? | How would response be measured, and what findings would lead the treating team to continue, adjust, or stop treatment? | Focuses on monitoring and decision points |
Is it safe? | Which risks are most relevant given the patient’s organ function, medicines, and medical history? | Connects safety to the individual case |
How long will treatment take? | What determines the treatment schedule, when is response normally assessed, and what could change the timeline? | Avoids treating an estimate as a guarantee |
How much will it cost? | Which consultations, tests, medicines, hospital services, and follow-up expenses are included or excluded from the estimate? | Defines the scope of the estimate |
Can we travel to China? | Does the opinion identify a reason for in-person care, and what clinical and administrative conditions remain unresolved? | Separates medical value from travel logistics |
Can this cure the cancer? | What is the intended goal of the proposed treatment, and what limitations should the patient understand? | Replaces an absolute question with a clinically answerable one |
Why Does Record Preparation Affect the Questions a Specialist Can Answer?
A specialist can only comment on the information made available for review.
Depending on the case, the submitted file may need to include:
pathology reports;
radiology reports;
original CT, MRI, or PET-CT image files;
surgery and discharge summaries;
radiotherapy records;
systemic-treatment names, dates, and doses;
treatment-response assessments;
recent laboratory results;
genomic or molecular testing;
current medicines and allergies;
relevant chronic-condition history;
a concise chronological summary.
Not every case requires every document. The receiving physician or institution determines what is clinically necessary. MedBridgeNZ may check whether documents requested by the physician or institution have been supplied, labelled, formatted, and translated for administrative submission. Only the consulting physician or institution can determine whether the records are clinically sufficient.
Medical records should only be translated, transferred, or discussed with the patient’s authorisation or the authority of an appropriate legal representative.
Preparing documents for a remote specialist review:
MedBridgeNZ can coordinate medical-record formatting, translation, and administrative submission when a patient has identified a requested specialty or consultation purpose. Clinical interpretation remains the responsibility of the consulting physician.
Clinical Case Study
What a Structured Question List Helped Clarify
This case has been de-identified and selectively generalised to protect patient privacy. It illustrates the remote consultation and administrative coordination process only. It does not represent a standard treatment pathway or predict outcomes for other patients.
Patient Profile
An adult patient living outside China had advanced cancer that had progressed after previous systemic treatment. The family was considering an overseas specialist opinion and wanted to understand whether another treatment pathway warranted discussion. The submitted records also described new symptoms, relevant medical history, and a molecular test result that required specialist interpretation.
Initial Recommendation
Because important questions remained about the patient’s current condition, possible next steps, and the practicality of international travel, a record-based specialist second opinion was arranged before any medical trip was planned. The available pathology, imaging information, previous treatment records, clinical summary, and prioritised questions were compiled and translated for submission through an available oncology consultation pathway in China.
Why a Second Opinion Was Sought
The family wanted the specialist to clarify:
which treatment options might warrant discussion with the current oncology team;
whether further imaging, laboratory testing, or pathology review was required;
how treatment benefit would normally be assessed;
which common and serious risks should be considered;
whether suggested tests or treatment could be discussed locally;
whether an in-person assessment in China was medically necessary;
which hospital and travel requirements would need separate confirmation.
These questions helped define the purpose of the consultation rather than asking the specialist to provide a general list of every possible treatment.
Multidisciplinary Review
This case did not involve a documented formal multidisciplinary tumour board.
The process consisted of a specialist oncology review together with separate administrative clarification from the receiving institution. The specialist addressed more than the possibility of another anticancer treatment. The review also considered:
whether the patient’s new symptoms required local attention;
whether current health concerns could affect treatment tolerance;
what additional information might be needed;
how treatment response could be monitored;
the relevance and limitations of the molecular test result;
whether long-distance travel was appropriate at that stage.
The administrative clarification also showed that specialist review, hospital acceptance, travel documentation, and treatment arrangements were separate processes.
Outcome
The consultation did not result in an instruction to travel to China immediately.
Instead, it identified issues that should first be discussed with the patient’s existing medical team. The family was advised to use the report as an additional clinical perspective and to explore whether any suggested investigations or treatment discussions could take place locally. The review also clarified that any future in-person pathway would remain subject to:
the patient’s current medical condition;
updated tests and examination;
the receiving institution’s requirements;
confirmation of travel suitability;
applicable administrative arrangements.
The final report functioned as a second medical opinion based on submitted records. It was not a direct prescription or mandatory treatment instruction.
The case illustrates why a remote oncology consultation should not be limited to asking: What treatment is available overseas?
A more useful question may be: What should be clarified next, what can be addressed locally, and what would genuinely require an in-person assessment?
Please note: Individual medical outcomes vary significantly depending on baseline health, prior treatments, and specific disease progression.
Who Should Use This Checklist?
This checklist may be relevant when:
a patient is seeking another oncology perspective;
treatment has stopped controlling the disease;
pathology or genomic findings require specialist interpretation;
a family is considering treatment in China;
the existing team has suggested obtaining another opinion;
travel would require significant medical and administrative preparation.
It is intended for non-emergency specialist review. A remote consultation should not delay local medical care when:
symptoms are severe or rapidly worsening;
emergency assessment may be required;
the patient needs urgent hospital admission;
immediate imaging, symptom control, or a procedure is needed;
the available records no longer reflect the current condition.
MedBridgeNZ does not perform emergency triage, medically screen patients, certify fitness to fly, or determine treatment eligibility.
How Does MedBridgeNZ Coordinate Question and Record Submission?
International patients may hold medical records from several hospitals, written in different formats and covering different stages of treatment. MedBridgeNZ can:
compile the documents submitted by the patient;
format the medical timeline;
translate medical records and prioritised questions;
check whether documents requested by the physician or institution have been supplied;
route the file through an available institutional channel;
coordinate consultation scheduling;
facilitate communication about administrative requirements.
Patients who need broader support beyond document preparation can review MedBridgeNZ’s medical concierge services, including medical-record translation, remote specialist coordination, hospital navigation, and travel logistics.
Administrative specialist matching is based on the diagnosis stated in the submitted records, the requested specialty, and the purpose of the review. The consulting physician performs the clinical interpretation and determines whether the available information is medically sufficient.
Frequently Asked Questions
What pathology and imaging records should I send before a remote oncology consultation with a Chinese cancer center?
Requirements vary by institution, department, specialist, and clinical question.
The requested file may include pathology reports, original slides or digital pathology, radiology reports, DICOM imaging, treatment summaries, laboratory results, and genomic reports. Ask which documents have been received and whether anything material is missing before the specialist begins the review.
Should I ask whether CT, MRI, or PET-CT will be used to assess treatment response?
Yes. Ask which imaging method is relevant to the specific cancer, what baseline imaging is required, when response would normally be assessed, and what could alter the schedule. PET-CT should not be assumed to be necessary simply because it was used previously.
How should I ask about a BRAF mutation or another genomic alteration?
Ask whether the alteration is clinically relevant to the specific cancer type, whether it is classified as pathogenic or uncertain, and whether it has an evidence-supported treatment implication. Also ask whether confirmatory testing or additional molecular analysis is required.
What should I ask when cancer has progressed after previous treatment?
Ask how the timing and pattern of progression affect the remaining options, whether the previous treatment should be considered ineffective, and what further pathology, imaging, or laboratory information is required before another approach can be discussed. The specialist should also explain how previous treatment toxicity and the patient’s current health may affect subsequent options.
Can my local oncologist use a Chinese specialist’s second-opinion report?
The report can be shared with the local treating team for discussion. The local oncologist may examine the rationale, determine whether the suggested tests or medicines are available, and decide whether any part of the opinion is appropriate in the patient’s current setting. The overseas report should not be treated as a direct prescription.
Can a family member prepare the questions and join the remote oncology consultation?
A family member may help organise the clinical timeline, prioritise questions, and take notes, subject to the patient’s consent, applicable privacy requirements, and the consultation format used by the physician or institution. Identity, authorisation, and communication requirements should be confirmed before the consultation.
Preparing a Structured Remote Consultation Request
A useful consultation request should make the main decision clear, provide the records needed to examine that decision, and separate clinical questions from travel and hospital-administration questions.
1. Initial Case Intake
The patient submits available medical records, imaging reports, and prioritised questions.
MedBridgeNZ can compile, format, and translate the documents so they can be routed in a structured form through an available Chinese institutional consultation pathway.
2. Administrative Specialist Matching and Consultation Setup
Based on the diagnosis stated in the submitted records, the requested specialty, and the purpose of the review, MedBridgeNZ can facilitate administrative specialist matching and consultation scheduling, subject to physician and institutional availability.
The consulting physician performs the medical review and provides the clinical opinion.
3. On-the-Ground Coordination
When the patient, treating physicians, and receiving institution subsequently confirm an in-person pathway, MedBridgeNZ can coordinate appointment scheduling, hospital-system navigation, bilingual accompaniment, transportation, and accommodation arrangements.
Patients preparing for a remote oncology second opinion may submit their diagnosis summary, available records, and main consultation question through the MedBridgeNZ Contact Us page. The bilingual Patient Care Team can explain the document, translation, and administrative coordination requirements for the requested pathway.
References
National Cancer Institute. “Finding Cancer Care: Getting a Second Opinion After a Cancer Diagnosis.” https://www.cancer.gov/about-cancer/managing-care/finding-cancer-care
National Cancer Institute. “Questions to Ask Your Doctor about Treatment.” https://www.cancer.gov/about-cancer/treatment/questions
National Cancer Institute. “Questions to Ask Your Doctor about Your Diagnosis.” https://www.cancer.gov/about-cancer/diagnosis-staging/questions
National Cancer Institute. “Questions to Ask Your Doctor about Advanced Cancer.” https://www.cancer.gov/about-cancer/advanced-cancer/questions
National Cancer Institute. “Biomarker Testing for Cancer Treatment.” https://www.cancer.gov/about-cancer/treatment/types/biomarker-testing-cancer-treatment
National Cancer Institute. “Side Effects of Cancer Treatment.” https://www.cancer.gov/about-cancer/treatment/side-effects
Shah, A. P., et al. “Virtual Second-Opinion Delivery for Oncology Patients.” Journal of Clinical Oncology Oncology Practice, 2025. https://pubmed.ncbi.nlm.nih.gov/39933116/
Disclaimer: MedBridgeNZ acts strictly as an international medical concierge and logistics coordinator. We do not provide direct medical treatment, diagnosis, or clinical advice. This content is for informational purposes only and does not constitute medical guidance. Always consult your primary physician or treating oncologist before pursuing cross-border treatment options.
